期刊文献+

单剂量赛尼哌联合新赛斯平预防肾移植急性排斥反应的研究 被引量:1

Preventive Effect of Simplex Dosage Zenapax in Combination with CsA on Acute Rejection after Kidney Transplantation
暂未订购
导出
摘要 目的观察使用单剂量赛尼哌联合环孢素(新赛斯平胶囊)对肾移植术后急性排斥反应的预防作用,并对其安全性进行评估。方法将同期行肾移植的80例病人分为对照组和治疗组各40例,除了治疗组术前使用赛尼哌外,两组病人术后治疗方案相同。结果治疗组6个月内急性排斥反应发生率(7.5%)显著低于对照组(25%),在感染及毒副作用方面两组无显著性差别。结论肾移植术前应用单剂量赛尼哌联合新赛斯平胶囊,能有效预防肾移植术后急性排斥反应发生,且经济、安全有效。 Objective To observe the preventive effect of simplex dosage zenapax in combination with CsA on acute rejection after kidney transplantion. Methods A total of 80 renal transplant recipients were divided into both the treatment and control groups of forty cases each. There were no difference in postoperative treatment plan between both the groups, but the simplex dosage zenapax was preoperatively given to each patient of the treatment group and not to each one of the control group. Results Acute rejection rate was significantly lower in the treatment group (7.5%) than that in the control group (25.0%) within 6months ( P 〈 0.05 ). There were insignificant difference in infection and side effect between both the group. Conclusion It is effective, economical and secure to use simplex dosage zenapax in combination with CsA for the prevention of acute rejection after renal tranplantation.
机构地区 解放军
出处 《华南国防医学杂志》 CAS 2006年第1期10-12,共3页 Military Medical Journal of South China
关键词 肾移植 赛尼哌 急性排斥反应 Kidney transplantation Zenapax Acute rejection
  • 相关文献

参考文献7

  • 1[1]Ekberg H,Backman L,Tuf verson G,et al.Daclizumab prevents acute rejection and improves patient survival posttransplantation:1 year pooled analysis.TransplantInt,2000,13 (1):151 ~ 159
  • 2[2]Lorranine C,Kim S,Robert B,et al.The Banff 97 working classification of renal allograft pathology.Kidney Inter,1999,55(7):713 ~723
  • 3[3]Pzepiorka D,Keman NA,Ippoliti C et al.Daclizumab,a humanized antiinterleukin -2 receptor alpha chain antibody,for treatment of acute graft-versus-host disease.Am Soci Hematol,2000,95(1):83 ~ 87
  • 4[4]Goebel J,Stevens E,Forrest K,et al.Daclizumab block early interleukin-2 receptorsingaling.The eighteenth transplant meeting of all the world,2000.528 ~ 533
  • 5[5]Ekberg H,Backman L,Tufverson G,et al.Daclizumab reduces the incidence of acute rejection and improves patient survival posttransplantation.Transplant Proc,1999,31 (1):267 ~ 293
  • 6[6]Nashan B,Light I,Hardie 1 et al.Reduction of acute renal allograft rejection by daclizumab.Transplantation,1999,67 (1):110~116
  • 7[7]Chang G,Mahanty H,Vincenti F,et al.A calcineurin inhibitorsparing regimen with sirolimus,mycophenolate mofetil,and anti-cd25 mab provides effechve immunosuppression in kidney transplant recipients with delayed or impaired graft function.Clin Transplant,2000,14 (6):550 ~ 560

同被引文献5

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部